PicnicHealth and Komodo Health Have Combined Their Data to Better Serve Multiple Sclerosis and Hemophilia Patients

Komodo Health and PicnicHealth have just announced that they have partnered together in effort to combine their data and better serve patients. This data will then be made accessible to…

Continue Reading PicnicHealth and Komodo Health Have Combined Their Data to Better Serve Multiple Sclerosis and Hemophilia Patients
Biogen’s Recent Progress in Relapsing Multiple Sclerosis Presented at the 2021 Meeting of the AAN
source: pixabay.com

Biogen’s Recent Progress in Relapsing Multiple Sclerosis Presented at the 2021 Meeting of the AAN

According to an article in Biospace, Biogen, a biotechnology company headquartered in Cambridge, Massachusetts, presented new data on its multiple sclerosis (MS) therapies at the virtual Meeting of the American…

Continue Reading Biogen’s Recent Progress in Relapsing Multiple Sclerosis Presented at the 2021 Meeting of the AAN
AI Used to Identify 3 MS Subtypes
Source: Pixabay.com

AI Used to Identify 3 MS Subtypes

Currently, multiple sclerosis (MS), an autoimmune and neurological disorder, is considered either progressive or relapsing-remitting. But could there be additional subtypes? According to new research, yes. As explained in Medical…

Continue Reading AI Used to Identify 3 MS Subtypes
New Multiple Sclerosis Drug Rejected by NICE
https://pixabay.com/en/denied-insurance-rejected-stamp-1936877/

New Multiple Sclerosis Drug Rejected by NICE

The National Institute for Health and Clinical Excellence (NICE), an agency under the UK's National Health Service (NHS), has recently rejected Zeposia. Zeposia is an oral, multiple sclerosis (MS) treatment…

Continue Reading New Multiple Sclerosis Drug Rejected by NICE
Experimental Treatment Reduces Retinal Thinning in Progressive Multiple Sclerosis
source: pixabay.com

Experimental Treatment Reduces Retinal Thinning in Progressive Multiple Sclerosis

According to a story from GlobeNewswire, the biopharmaceutical company MediciNova, Inc. has announced encouraging results related in Optical Coherence Tomography (OCT) in a phase 2b clinical trial. This clinical trial…

Continue Reading Experimental Treatment Reduces Retinal Thinning in Progressive Multiple Sclerosis
Preclinical Data Supports NurOwn for ALS, MS, and Alzheimer’s Disease
Source: Pixabay

Preclinical Data Supports NurOwn for ALS, MS, and Alzheimer’s Disease

  Within the last month, BrainStorm Cell Therapeutics Inc. announced the publication of pre-clinical data on the NurOwn system. NurOwn technology produces autologous, bone marrow-derived mesenchymal stem cells (MSCs) for…

Continue Reading Preclinical Data Supports NurOwn for ALS, MS, and Alzheimer’s Disease